Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug;35(8):1323-1335.
doi: 10.1002/mds.28201. Epub 2020 Jul 15.

Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial

Anne-Catherine Bachoud-Lévi  1   2   3 ; on behalf the Multicentric Intracerebral Grafting in Huntington's Disease Group
Collaborators, Affiliations
Clinical Trial

Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial

Anne-Catherine Bachoud-Lévi et al. Mov Disord. 2020 Aug.

Abstract

Background: Huntington's disease is a rare, severe, inherited neurodegenerative disease in which we assessed the safety and efficacy of grafting human fetal ganglionic eminence intrastriatally.

Methods: Patients at the early stage of the disease were enrolled in the Multicentric Intracerebral Grafting in Huntington's Disease trial, a delayed-start phase II randomized study. After a run-in period of 12 months, patients were randomized at month 12 to either the treatment group (transplanted at month 13-month 14) or the control group and secondarily treated 20 months later (month 33-month 34). The primary outcome was total motor score compared between both groups 20 months postrandomization (month 32). Secondary outcomes included clinical, imaging, and electrophysiological findings and a comparison of pregraft and postgraft total motor score slopes during the entire study period (month 0-month 52) regardless of the time of transplant.

Results: Of 54 randomized patients, 45 were transplanted; 26 immediately (treatment) and 19 delayed (control). Mean total motor score at month 32 did not differ between groups (treated controls difference in means adjusted for M12: +2.9 [95% confidence interval, -2.8 to 8.6]; P = 0.31). Its rate of decline after transplantation was similar to that before transplantation. A total of 27 severe adverse events were recorded in the randomized patients, 10 of which were related to the transplant procedure. Improvement of procedures during the trial significantly decreased the frequency of surgical events.We found antihuman leucocytes antigen antibodies in 40% of the patients.

Conclusion: No clinical benefit was found in this trial. This may have been related to graft rejection. Ectopia and high track number negatively influence the graft outcome. Procedural adjustments substantially improved surgical safety. (ClinicalTrials.gov NCT00190450.) © 2020 International Parkinson and Movement Disorder Society.

Keywords: Huntington's disease; MIG-HD; cell therapy; phase 2 trial.

PubMed Disclaimer

Comment in

  • A Failed Future.
    Albin RL, Kordower JH. Albin RL, et al. Mov Disord. 2020 Aug;35(8):1299-1301. doi: 10.1002/mds.28130. Mov Disord. 2020. PMID: 32780511 No abstract available.

References

    1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
    1. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10:204-216.
    1. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
    1. Palfi S, Condé F, Riche D, et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998;4:963-966.
    1. Dunnett SB, Nathwani F, Björklund A. The integration and function of striatal grafts. Prog Brain Res 2000;127:345-380.

Publication types

Associated data